Dr-Yuanbin Chen

ASCO20: IMFINZI plus Chemotherapy For Extensive-Stage Small Cell Lung Cancer

MedicalResearch.com Interview with:

Dr-Yuanbin Chen

Dr. Chen

Yuanbin Chen, MD, PhD
Cancer & Hematology
Centers of Western Michigan

MedicalResearch.com: What is the background for this study? What are the main findings?

    • Response: The CASPIAN trial was a randomized, open-label, multi-center global Phase III trial in the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The trial compared IMFINZI in combination with etoposide and either carboplatin or cisplatin chemotherapy, or IMFINZI and chemotherapy with the addition of a second immunotherapy, tremelimumab, versus chemotherapy alone – the primary endpoint being overall survival (OS). After a median follow up of more than two years, the latest results for IMFINZI plus chemotherapy demonstrate a sustained and clinically meaningful OS benefit for patients with extensive-stage small cell lung cancer (ES-SCLC), maintaining a 25% reduction in the risk of death versus chemotherapy alone. Updated median OS was 12.9 months versus 10.5 for chemotherapy.
      • In a post-hoc analysis, 22.2% of patients treated with IMFINZI plus chemotherapy remained alive after 24 months, versus 14.4%, for chemotherapy alone.
      • Post-hoc analysis also showed that for IMFINZI plus chemotherapy, 11.0% of patients were alive and progression-free at 24 months versus 2.9% for chemotherapy alone.
      • IMFINZI plus chemotherapy maintained a high confirmed objective response rate (ORR) (68% versus 58%) and in a post-hoc analysis, duration of response (DoR) for IMFINZI at 24 months was 13.5% versus 3.9% for chemotherapy alone.
      • At 24 months, 12% of patients in the IMFINZI plus chemotherapy arm remained on IMFINZI treatment.]

MedicalResearch.com: What should readers take away from your report?

Response: These data reinforce IMFINZI plus chemotherapy as an important new 1st-line standard of care for extensive-stage small cell lung cancer patients in the US, and this regimen offers patients convenient dosing every four weeks during maintenance.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: The CASPIAN trial will continue to assess overall survival as its primary endpoint, and we look forward to sharing the ongoing data in due course. 

MedicalResearch.com: Is there anything else you would like to add?

    • SCLC is a devastating disease where improving outcomes has been a challenge.  There is an urgent need for new medicines to improve survival in extensive-stage disease , which affects about two-thirds of SCLC patients  and where patients relapse quickly following initial chemotherapy. Prognosis is particularly poor in this setting, with only 3% of patients alive five years after diagnosis. We are committed to harnessing the power of immuno-oncology with the hope that it will deliver improved treatment outcomes for patients with small cell lung cancer in urgent need of new options.

      Disclosures: Honorarium for advisory board or speaker faculty: AstraZeneca, Bristol-Myer Squib, IPSEN, Merck, Takeda, Pfizer, Eli-Lilly, Amgen, Guardant Health. 


Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.

Luis G. Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Oleksandr Voitko, Artem Poltoratskiy, Francesco Verderame, Libor Havel, Igor Bondarenko, Jon Armstrong, Natalie Byrne, Haiyi Jiang, and Jonathan Wade Goldman

Journal of Clinical Oncology 2020 38:15_suppl, 9002-9002




The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.


Last Updated on June 13, 2020 by Marie Benz MD FAAD